Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-05

Study Completion Date

2019-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is two-fold. In the first phase, the goal is to characterize the stability of respiratory (nasal swab, nasopharyngeal swab, and throat swab; NS, NPS, TS) and stool (raw stool and rectal swab) specimens collected using various standard, medically established procedures with and without transport media and tested at various time points and under different temperature conditions, and also to look at variation between repeat sampling events. The intention is for these data to support decisions made by BioFire regarding the appropriate specimen type and handling guidelines for future tests. In the second phase of the study, collection and transport conditions identified in Phase 1 will be used to collect specimens for pilot performance evaluations of a new molecular diagnostic test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collection of Anonymized Samples

NCT03319446

Healthy Respiratory Disease Gastrointestinal Disease

ENROLLING_BY_INVITATION

Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting

NCT02232711

Upper Respiratory Infections

COMPLETED

Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2

NCT03012217

Upper Resp Tract Infection

COMPLETED

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136

Respiratory Tract Infections Influenza, Human Common Cold

COMPLETED NA

Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial

NCT06605352

Community-Acquired Pneumonia (CAP) Pneumonia

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This evaluation will be initiated at several sites in the US. In the first phase of the study, multiple specimens will be collected from each subject and tested using various pre-analytical techniques. Current BioFire FilmArray test panels will be used to assay each specimen and evaluate the multiple variables: repeat sampling, native specimen stability, or other post-collection variables. In the second phase of the study only two specimens will be collected from each subject: one for testing with the new test (using handling procedures identified in Phase 1) and another for testing with the reference method. Up to 2,000 subjects will be enrolled across all sites in each phase (up to 4,000 subjects total). Enrollment is expected to last approximately 18 months to cover both phases of the study. All specimens and subject data will be de-identified and coded. Prior to study initiation, each participating site will have the necessary Institutional Review Board (IRB) reviews. Specimens in both phases will be tested at the study site using various BioFire test platforms and cartridges.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Tract Infections Gastrointestinal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Respiratory/Pharyngitis

Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue

BioFire test platform

Intervention Type DIAGNOSTIC_TEST

Analysis of analyte stability under various conditions as measured by BioFire test platforms

Gastrointestinal

Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days

BioFire test platform

Intervention Type DIAGNOSTIC_TEST

Analysis of analyte stability under various conditions as measured by BioFire test platforms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BioFire test platform

Analysis of analyte stability under various conditions as measured by BioFire test platforms

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue. OR Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
* If age 18 or over, subject provides written informed consent
* If under the age of 18, parental permission and assent (as appropriate) is obtained
* Subject is willing and able to provide at least two (up to three) specimens: any combination of NS, NPS, or TS OR rectal swab or stool

Exclusion Criteria

* Subject is unable to provide consent or parental permission and assent (as appropriate) cannot be obtained
* Subject is unable or unwilling to provide two specimens
* Subject's health care provider determines that specimen collection represents an unacceptable risk

Eligible Sex

ALL

Accepts Healthy Volunteers

No